INDEPENDENT STRATEGIC ADVISOR
Strategy where science, technology and business meet.
I advise CEOs, founders, boards and organizations on strategy, partnerships, growth and complex innovation decisions, with particular depth across healthcare, life sciences and AI.
Strategy · Partnerships · Growth
CHF 20M+
Capital raised
20+
Cross-functional team built and led
10 years
Founder & CEO
Europe + US
Corporate, biotech and clinical partnerships
Strategic support where the decisions are consequential.
01
Strategy & Growth
Strategic direction, positioning, business models, commercialization, portfolio choices and strategic pivots.
02
Partnerships & Transactions
Partner strategy, business development, collaboration design, negotiation and strategic transactions.
03
AI, Technology & Innovation
Identifying where emerging technology, AI and data can create genuine organizational and commercial value.
04
CEO & Founder Advisory
Growth, financing, governance, stakeholder management and difficult strategic decisions.
An operator’s perspective, not an outside playbook.
I advise from experience having personally carried responsibility for difficult decisions and their consequences.
As Co-Founder and CEO of Scailyte, I built and led an AI-driven precision medicine company through fundraising, product development, pharmaceutical and biotech partnerships, team building, boards and investors, commercialization, strategic pivots and transactions.
I raised more than CHF 20 million, built a multidisciplinary team of more than 20 people and worked with corporate, biotech, clinical and academic partners across Europe and the US.
SELECTED EXPERIENCE
Scailyte
Co-Founder & CEO
UZH.ai
Head of Industry Partnerships
CEO-CF
Group Chair
Witec / Fluidigm
Swiss Market Development
PERSPECTIVES
A point of view on what is changing.
AI only matters when it becomes part of how the organization works.
Healthcare and life sciences already have plenty of AI pilots. The bigger challenge is fragmented systems, manual workflows and data trapped in silos. Sustainable value comes from connecting that infrastructure and embedding AI into daily processes where its impact can actually be measured.
Data is becoming a product, and increasingly a discovery platform.
The emerging TechBio model is shifting value from simply owning or selling biological data toward turning unique datasets into discovery engines. Research hospitals, genomics programs and other data-rich organizations can increasingly become technology and discovery partners to pharma.
Better AI in biology starts with better biology.
The quality, depth and context of biological and clinical data increasingly determine what AI can discover. High-resolution, multimodal and well-annotated patient data can create a stronger competitive advantage than applying another general model to the same datasets everyone already has.
HOW I WORK
Senior involvement, pragmatic execution.
Focused
I engage selectively where my experience, network and perspective can materially affect the outcome.
Hands-on
I move comfortably between strategy and execution, from defining the problem to shaping partnerships, negotiations and concrete next steps.
Independent
My role is to challenge assumptions, create clarity and help decision-makers reach stronger outcomes, not to sell a predetermined solution.
Flexible by design.
Engagements are shaped around the problem rather than a fixed consulting methodology.
Ongoing CEO, founder or leadership sparring.
Defined questions, decisions or market opportunities.
Partner identification, opportunity shaping and deal support.
Leadership, strategy and stakeholder alignment.
LET’S TALK
Have a strategic challenge worth discussing?
I am always interested in ambitious organizations, difficult questions and opportunities where science, technology and business intersect.